BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 25, 2026
Home » Newsletters » BioWorld

BioWorld

June 2, 2020

View Archived Issues
Coronavirus vaccine, therapeutic illustration

Biopharma builds arsenal, launches showdown to squash COVID-19

Swept up into a coronavirus whirlwind, the biopharma industry has ramped up development of therapeutics and vaccines and altered business plans to fight the SARS-CoV-2 virus in a way that nobody could have imagined only months ago. Read More

Roche TIGIT bid wows ASCO, upper rung in lung; Fc main key?

A key opinion leader (KOL) consulted by SVB Leerink deemed Roche Holding AG’s anti-TIGIT drug results “really huge” and “quite amazing,” affirming the Basel, Switzerland-based firm’s lead in the field. The phase II data from the study known as Cityscape rolled out at the virtual American Society of Clinical Oncology (ASCO) meeting. Read More
cancer-AI-diagnostic.png

Investors impressed by companies presenting at ASCO

Overall, data presented at the American Society of Clinical Oncology virtual meeting over the weekend appear to have garnered investor approval, with the BioWorld Cancer index advancing 3%, by market close Monday, and a further 1.7% by the closing bell today. Read More

Tenax shares rise as company finds new path for levo

Levosimendan's long story took a new turn with results from a phase II trial testing chronic administration of the calcium sensitizer in patients with pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF). Read More
Antibiotics-petri-dish.png

Retargetable platforms are possible answer to antimicrobial woes

In emergency situations, broad-spectrum antibiotics have their place. But their indiscriminate use has led to a resistance crisis that already kills tens of thousands of people annually in the U.S. alone. Read More

A mighty wind: Chinook, Aduro to merge, with focus on kidney disease

Aduro Biotech Inc. and privately held Chinook Therapeutics Inc., will merge to focus mainly on kidney diseases. Two complementary drugs are involved in the deal. Read More
China U.S. deal

Beijing startup Jacobio brings Abbvie aboard in SHP2 collaboration

BEIJING – Five-year-old Jacobio Pharmaceuticals Co. Ltd., of Beijing, has found itself a strong global partner to help advance its two SHP2 inhibitors, JAB-3068 and JAB-3312, both financially and later in the regulatory process. The Chinese startup will work with pharma giant Abbvie Inc., of North Chicago, to develop and commercialize the programs. Read More
Photograph of two bioelectronic implants with a coin (diameter 27.4 mm) for comparison

Researchers combine bioelectronic implants, engineered beta cells to express insulin in mice

Investigators are working to develop electrogenetic devices that use remote-controlled electrical stimulation to elicit specific behaviors in engineered cells. They are following in the footsteps of optogenetics, which use specific wavelengths of light to control cell function remotely. A new study published in Science used such a device paired with encapsulated, engineered human pancreatic beta cells to express enough insulin to restore normal glycemic levels in mice models of diabetes. Read More

Appointments and advancements for June 2, 2020

New hires and promotions in the biopharma industry, including: Calcimedica. Read More

Financings for June 2, 2020

Biopharmas raising money in public or private financings, including: Adaptimmune, Allogene, Applied Molecular Transport, Argenx, Biocryst, Bionomics, Calliditas, Circassia, G1 Therapeutics, Humanigen, Pliant, Sareum. Read More

In the clinic for June 2, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aduro, Ameri, Asana, Bergenbio, Beyondspring, Brainstorm, BMS, Idera, Innovent, Menlo, Mirum, Moleculin, Neurorx, Nicox, Northwest, Orphomed, Regenerx, Relief, Sanofi, Santhera, Satsuma, Tenax. Read More

Other news to note for June 2, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Agenus, Agex, Alize Pharma 3, Aqualung, Astronautx, Aytu, Biodtech, CSL Behring, Delta 4, Egenesis, Epivax, Hemogenyx, Hesperos, Imstem, Intravacc, Inventabiotech, Melinta, Modular, Personalis, Pfizer, Predictive, Sarepta, Siga, Soluble, Tetraphase, Trevena, Valirx, Vitro, Vivus, Vizuri. Read More

Regulatory actions for June 2, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agenus, Braeburn, Cellenkos, Citius, Helsinn, Nkmax, Renovorx, Rigenerand, Sapience, Tetra Bio-Pharma, Y-mabs. Read More

Regulatory front for June 2, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Amneal, Apotex. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing